Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2017: Volume 22/ Issue 3 Article 2
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 22, Issue 3, 19 January 2017
Rapid communication
Penot, Brichler, Guilleminot, Lascoux-Combe, Taulera, Gordien, Leparc-Goffart, and Molina: Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016

+ Author affiliations


Citation style for this article: Penot P, Brichler S, Guilleminot J, Lascoux-Combe C, Taulera O, Gordien E, Leparc-Goffart I, Molina J. Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016. Euro Surveill. 2017;22(3):pii=30444. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.3.30444

Received:23 December 2016; Accepted:18 January 2017


A female patient returned to France from the Caribbean islands with acute Zika virus infection. After obtaining informed consent, we collected vaginal swabs for both RNA detection and virus culture in order to investigate the infectivity of vaginal secretions.

Case presentation

A French woman in her 40s, with a controlled HIV-1 infection, travelled to French Caribbean islands (Martinique for seven days then Guadeloupe for three weeks) in summer 2016. On the day of return to France, she felt asthenic with myalgia. Two days later, a pruritic rash appeared on her face, chest, back and arms, with abdominal pain and diarrhoea. She consulted her general practitioner, who referred her to our department on the same day.

Her medical history was limited to a virologically suppressed HIV-1 infection with CD4+ T-cell count over 500/mm3 under antiretroviral therapy (emtricitabine/tenofovir and nevirapine). Physical examination showed a widespread itching maculopapular exanthema, conjunctival hyperaemia and mild fever (38.1 °C). Intense asthenia and diffuse myalgia were still ongoing.

As the symptoms were consistent with acute Zika virus infection, the patient consented to have a vaginal swab, after being informed that there would be no direct benefit from knowing the test result. In the absence of a standardised collection protocol, vaginal secretions were collected by direct swab (vaginal sample 1) and after instilling 5 mL of saline solution between the cervix and the posterior vaginal wall (vaginal sample 2). At her request, her scheduled cervical Pap smear was performed at the same time.

Standard laboratory tests showed moderate lymphocytopenia with 1,120 cells/mm3 (norm: > 1,200/mm3) and C-reactive protein 8 mg/L (norm: < 5 mg/L). RT-PCR assays were negative for dengue and chikungunya viruses in plasma (Fast-Track Diagnostics, Luxembourg) and a test for NS1 antigen for dengue virus was also negative (Bio-Rad, Marne la Coquette, France). Detection of Zika virus RNA by RT-PCR (Altona Diagnostics, Hamburg, Germany) was positive in plasma, urine and vaginal secretions, three days after onset of symptoms. The viral RNA load was 3.8 log copies/mL in plasma, 6.1 in urine, 5.3 in vaginal sample 1 and 3.9 in vaginal sample 2. The use of a saline solution instillation for the second sampling possibly led to a dilution of the sample. The two vaginal samples were inoculated on Vero and C6/36 cells, and Zika virus was isolated from both, demonstrating the presence of infective Zika virus. All methods were performed as detailed in the supplementary data of a previous publication [1]. According to French guidelines, no serological analysis was performed for dengue and Zika viruses.

The patient’s fever subsided on day 3, and the rash on day 6 after symptom onset. A transient bilateral knee pain occurred on day 4.

The patient consented to a second genital swab 10 days after the onset of symptoms: no viral RNA was detected in vaginal secretions and in cervical mucus. No serum collection was performed during the second visit. At that time, she had recovered from all symptoms except a mild persistent asthenia. Her husband did not present symptoms evocative of Zika virus infection during or after the journey. The patient stated that their sexual intercourses were always protected by condom use.

Background

Initially, Zika virus was thought to be exclusively transmitted through mosquitoes, but sexual transmission was subsequently reported. Transmission from men to their female or male sexual partners has been well and often demonstrated and has been observed up to 44 days after symptom onset [2-5], whereas only one case report suggests a possible woman-to-man transmission, which was concurrent with the acute infection symptoms in the female partner [6]. Three teams have reported the presence of Zika virus RNA in female genital secretions up to 14 days after symptoms onset, but Zika virus infectivity was not proven [7-9]. None of the women with symptomatic Zika infection involved in an assisted reproductive technology programme on Guadeloupe had detectable Zika virus in their genital tract beyond the second week of follow up, despite regular monitoring by Zika RT-PCR for up to 3 months [7].

Discussion

This seldom reported and transient presence of Zika virus in the female genital tract contrasts with an extensive literature about its persistence in semen, where RNA has been detected up to six months after return from endemic areas [4,10-14]. Moreover, Zika virus from semen has been isolated in cell culture in four patients, up to 69 days after onset of symptoms, but had never been isolated from the human female genital secretions before [1,15-17].

The short time period during which we could detect Zika virus in our patient’s genital tract is consistent with our prior failure to detect the virus by RT-PCR from vaginal swabs in two other patients, seven and eight days after the onset of symptoms [18]. Although viral load was higher in our patient’s vaginal secretions than in her serum, it remained lower than what could be measured in some semen samples [1,15,16]. Our patient had been living with virologically HIV suppressed infection for years and had an almost normal lymphocyte cell count. It is unlikely that her HIV-infection influenced the evolution of her Zika virus infection, especially as the clinical presentation and evolution were similar to those observed in HIV-negative patients.

Recently, a mouse model of Zika virus infection by vaginal exposure demonstrated that Zika virus replicated within the genital mucosa and could lead to a fetal infection [19], but no data has been available up to now on the infectiousness of a vaginally situated virus in humans. Our findings suggest a short period of infectivity of women with acute Zika virus infection through their genital secretions. This short duration of virus shedding in genital secretion may explain why to date only one case of female to male transmission has been reported. Yet, it remains unknown whether Zika virus can establish a reservoir in the female genital tract and infect follicles and/or ovules.

Recent evidence of extended presence of the virus in semen and of possible transmission from women to men has led to an update of the United States Centers for Disease Control and Prevention (CDC)’s guidance on the prevention of sexual transmission of Zika virus [20]. Current French guidelines and the CDC recommend a deferral period of at least 2 months before women returning from an area with circulating Zika virus can access medically assisted reproductive technology programmes. When this delay cannot be adhered to (e.g. fertility preservation before chemotherapy), testing vaginal samples by RT-PCR should be recommended.


Acknowledgements

We thank Séverine Chereau, Natasha Clamy, Fabienne Corbel, Brigitte Aloccio, Radja Veron, Sylvie Quiavoloca and Sandra Vassallo.

Conflict of interest

None declared.

Authors’ contributions

Pauline Penot, Olivier Taulera, Caroline Lascoux-Combe took care of the patient; Pauline Penot and Jean Guilleminot sampled the genital swabs; Ségolène Brichler performed the PCR; Isabelle Leparc-Goffart isolated the virus; Pauline Penot wrote the first draft of the manuscript. All authors reviewed and approved the final manuscript.


References

  1. D’Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G,  et al.  Evidence of sexual transmission of Zika virus. N Engl J Med. 2016;374(22):2195-8. DOI: 10.1056/NEJMc1604449 PMID: 27074370

  2. Turmel JM, Abgueguen P, Hubert B, Vandamme YM, Maquart M, Le Guillou-Guillemette H,  et al.  Late sexual transmission of Zika virus related to persistence in the semen. Lancet. 2016;387(10037):2501. DOI: 10.1016/S0140-6736(16)30775-9 PMID: 27287833

  3. Russell K, Hills SL, Oster AM, Porse CC, Danyluk G, Cone M,  et al.  Male-to-female sexual transmission of Zika virus-United States, January-April 2016. Clin Infect Dis. 2017;64(2):211-3. DOI: 10.1093/cid/ciw692 PMID: 27986688

  4. Harrower J, Kiedrzynski T, Baker S, Upton A, Rahnama F, Sherwood J,  et al.  Sexual transmission of Zika virus and persistence in semen, New Zealand, 2016. Emerg Infect Dis. 2016;22(10):1855-7. DOI: 10.3201/eid2210.160951 PMID: 27454745

  5. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD,  et al.  Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis. 2011;17(5):880-2. DOI: 10.3201/eid1705.101939 PMID: 21529401

  6. Davidson A, Slavinski S, Komoto K, Rakeman J, Weiss D. Suspected female-to-male sexual transmission of Zika virus - New York City, 2016.MMWR Morb Mortal Wkly Rep. 2016;65(28):716-7. DOI: 10.15585/mmwr.mm6528e2 PMID: 27442327

  7. Prisant N, Breurec S, Moriniere C, Bujan L, Joguet G. Zika Virus genital tract shedding in infected women of childbearing age.Clin Infect Dis. 2017;64(1):107-9. DOI: 10.1093/cid/ciw669 PMID: 27682065

  8. Nicastri E, Castilletti C, Balestra P, Galgani S, Ippolito G. Zika virus infection in the central nervous system and female genital tract.Emerg Infect Dis. 2016;22(12):2228-30. DOI: 10.3201/eid2212.161280 PMID: 27617352

  9. Murray KO, Gorchakov R, Carlson AR, Berry R, Lai L, Natrajan M,  et al.  Prolonged detection of Zika virus in vaginal secretions and whole blood. Emerg Infect Dis. 2017;23(1):99-101. DOI: 10.3201/eid2301.161394 PMID: 27748649

  10. Matheron S, d’Ortenzio E, Leparc-Goffart I, Hubert B, de Lamballerie X, Yazdanpanah Y. Long-lasting persistence of Zika virus in semen.Clin Infect Dis. 2016;63(9):1264.PMID: 27470244

  11. Gaskell KM, Houlihan C, Nastouli E, Checkley AM. Persistent Zika virus detection in semen in a traveler returning to the United Kingdom from Brazil, 2016.Emerg Infect Dis. 2017;23(1):137-9. DOI: 10.3201/eid2301.161300 PMID: 27748650

  12. Barzon L, Pacenti M, Franchin E, Lavezzo E, Trevisan M, Sgarabotto D,  et al.  Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro Surveill. 2016;21(32):30316. DOI: 10.2807/1560-7917.ES.2016.21.32.30316 PMID: 27542178

  13. Atkinson B, Thorburn F, Petridou C, Bailey D, Hewson R, Simpson AJH,  et al.  Presence and persistence of Zika virus RNA in semen, United Kingdom, 2016. Emerg Infect Dis. 2017;23(4). DOI: 10.3201/eid2304.161692 PMID: 27997333

  14. Nicastri E, Castilletti C, Liuzzi G, Iannetta M, Capobianchi MR, Ippolito G. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016.Euro Surveill. 2016;21(32):30314. DOI: 10.2807/1560-7917.ES.2016.21.32.30314 PMID: 27541989

  15. Mansuy JM, Dutertre M, Mengelle C, Fourcade C, Marchou B, Delobel P,  et al.  Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect Dis. 2016;16(4):405. DOI: 10.1016/S1473-3099(16)00138-9 PMID: 26949027

  16. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau V-M. Potential sexual transmission of Zika virus.Emerg Infect Dis. 2015;21(2):359-61. DOI: 10.3201/eid2102.141363 PMID: 25625872

  17. Arsuaga M, Bujalance SG, Díaz-Menéndez M, Vázquez A, Arribas JR. Probable sexual transmission of Zika virus from a vasectomised man.Lancet Infect Dis. 2016;16(10):1107. DOI: 10.1016/S1473-3099(16)30320-6 PMID: 27676342

  18. Penot P, Balavoine S, Leplatois A, Brichler S, Leparc-Goffart I, Alloui AC,  et al.  Five cases of acute Zika virus infection in French women of reproductive age returning from Central and South America. Rev Med Interne. Forthcoming.

  19. Yockey LJ, Varela L, Rakib T, Khoury-Hanold W, Fink SL, Stutz B,  et al.  Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell. 2016;166(5):1247-1256.e4. DOI: 10.1016/j.cell.2016.08.004 PMID: 27565347

  20. Petersen EE, Meaney-Delman D, Neblett-Fanfair R, Havers F, Oduyebo T, Hills SL,  et al.  Update: interim guidance for preconception counseling and prevention of sexual transmission of Zika virus for persons with possible Zika virus exposure - United States, September 2016. MMWR Morb Mortal Wkly Rep. 2016;65(39):1077-81. DOI: 10.15585/mmwr.mm6539e1 PMID: 27711033



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.